Acadian Asset Management LLC purchased a new position in Glaukos Corporation (NYSE:GKOS) during the second quarter, Holdings Channel reports. The firm purchased 15,720 shares of the medical instruments supplier’s stock, valued at approximately $651,000.

Other institutional investors also recently modified their holdings of the company. American Century Companies Inc. raised its position in Glaukos Corporation by 2.6% in the first quarter. American Century Companies Inc. now owns 135,082 shares of the medical instruments supplier’s stock valued at $6,930,000 after buying an additional 3,458 shares in the last quarter. Great West Life Assurance Co. Can acquired a new position in Glaukos Corporation during the first quarter valued at approximately $102,000. Tocqueville Asset Management L.P. acquired a new position in Glaukos Corporation during the first quarter valued at approximately $487,000. Wells Fargo & Company MN raised its position in Glaukos Corporation by 73.2% in the first quarter. Wells Fargo & Company MN now owns 1,156,562 shares of the medical instruments supplier’s stock valued at $59,332,000 after buying an additional 488,730 shares in the last quarter. Finally, DUPONT CAPITAL MANAGEMENT Corp acquired a new position in Glaukos Corporation during the first quarter valued at approximately $776,000. 89.63% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Glaukos Corporation (NYSE:GKOS) traded up 3.28% during midday trading on Friday, reaching $37.50. 267,533 shares of the company’s stock were exchanged. Glaukos Corporation has a 12-month low of $28.26 and a 12-month high of $52.49. The stock’s market cap is $1.29 billion. The stock’s 50 day moving average is $40.38 and its 200-day moving average is $43.21.

COPYRIGHT VIOLATION NOTICE: This piece was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://theolympiareport.com/2017/08/12/acadian-asset-management-llc-purchases-new-position-in-glaukos-corporation-gkos.html.

GKOS has been the topic of several recent research reports. Piper Jaffray Companies reaffirmed a “buy” rating and set a $56.00 target price on shares of Glaukos Corporation in a report on Thursday, August 3rd. Roth Capital reduced their target price on shares of Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a report on Thursday, August 3rd. Zacks Investment Research raised shares of Glaukos Corporation from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Friday, July 21st. BidaskClub raised shares of Glaukos Corporation from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Finally, TheStreet lowered shares of Glaukos Corporation from a “c” rating to a “d+” rating in a report on Wednesday, May 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $52.33.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.